A clinical observational study of dinutuximab beta as first-line maintenance treatment for patients with high-risk neuroblastoma in China

A clinical observational study of dinutuximab beta as first-line maintenance treatment for patients with high-risk neuroblastoma in China

Abstract Background High-risk neuroblastoma (HR-NB) is associated with high metastatic and relapse rates that require intensive multimodal treatment. We evaluated the efficacy and safety of dinutuximab beta as first-line maintenance immunotherapy in pediatric patients with HR-NB in real-world clinic...

Full description

Saved in:
Bibliographic Details
Main Authors: Xuedi Yu, Suyi Kang, Junjie Ge, Jingfu Wang
Format: Article
Language:English
Published: BMC 2025-03-01
Series:BMC Pediatrics
Subjects:
High-risk neuroblastoma
Dinutuximab beta
GD2-antibody immunotherapy
GM-CSF
First-line maintenance
Chemotherapy
Online Access:https://doi.org/10.1186/s12887-025-05568-x
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s12887-025-05568-x

Similar Items